Athersys MultiStem Stem Cell Therapy Receives Orphan Drug Designation in Europe
December 17, 2013 at 07:01 AM EST
Athersys (Nasdaq: ATHX ) announced today that the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA) has issued a positive opinion (EMA/OD/146/13) for the Company's allogeneic, multipotent adult progenitor cell, or MultiStem® therapy, for the prevention of graft-versus-host disease (GvHD). The Company is developing its MultiStem
